The Brand Name RENOFIX-S Has Generic Salt :: Mycophenolate
RENOFIX-S Is From Company Unichem Priced :: Rs. 760
RENOFIX-S have Mycophenolate is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Prophylaxis of acute renal graft rejection
Drug Dose ::
Adult: PO Prophylaxis of acute renal graft rejection As mycophenolate mofetil (MMF): 1 g twice daily starting w/in 72 hr of transplantation. Max: 2 g/day. As mycophenolic acid: 720 mg twice daily. Prophylaxis of cardiac graft rejection As MMF: 1.5 g twice daily starting w/in 5 days after transplantation.
Pregnancy, lactation. Rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), including Kelley-Seegmiller or Lesch-Nyhan syndrome.
Drug Precautions ::
Teratogenic in animals; avoid inhalation or direct skin contact. Monitor patients for lymphoproliferative disorders; advise patient to limit exposure to sunlight/UV light. Active peptic ulcer disease. Severe renal impairment. Mycophenolate mofetil and mycophenolate sodium are not interchangeable. Perform CBCs; monitor for neutropenia.
Drug Side Effects ::
Diarrhoea, vomiting, GI haemorrhage and perforation; leucopenia; asthenia, pain, headache, anaemia, thrombocytopenia, renal tubular necrosis, haematuria, BP changes, hyperglycaemia, disturbances of electrolytes and blood lipids, peripheral oedema, dyspnoea, cough, acne, rash, alopecia, dizziness, insomnia, paraesthesia, tremor, hypersensitivity reactions, pancreatitis, hepatitis. Potentially Fatal: Angioedema, anaphylaxis, fatal pulmonary fibrosis.
Pregnancy category ::
Drug Mode of Action ::
Mycophenolic acid acts by blocking purine synthesis of human lymphocytes through reversible inhibition of inosine monophosphate dehydrogenase. It also inhibits proliferation of both T- and B- lymphocytes.
Drug Interactions ::
Increased plasma levels of both drugs when combined with aciclovir, valaciclovir, ganciclovir and valganciclovir. Reduced absorption with colestyramine, magnesium- and aluminium hydroxide-containing products, sevelamer and other calcium-free phosphate binders. Reduced plasma levels with ciclosporin, metronidazole, quinolones, rifamycins. May reduce plasma levels of progestins; may reduce efficacy of oral contraceptives. Increased plasma levels with probenecid. May reduce efficacy of live vaccines.